

# The CliniBook

**CLINICAL GENE TRANSFER:  
STATE-OF-THE-ART**

Éditions EDK/Groupe EDP Sciences  
25, rue Daviel  
75013 Paris, France  
Tél. : 01 58 10 19 05  
Fax : 01 43 29 32 62  
edk@edk.fr  
www.edk.fr

EDP Sciences  
17, avenue du Hoggar  
PA de Courtabœuf  
91944 Les Ulis Cedex A, France  
www.edpsciences.org

© Éditions EDK, Paris, 2012  
ISBN : 978-2-8425-4171-2

Il est interdit de reproduire intégralement ou partiellement le présent ouvrage – loi du 11 mars 1957 – sans autorisation de l'éditeur ou du centre Français d'exploitation du Droit de copie (CFC), 20, rue des Grands-augustins, 75006 Paris, France.



# The CliniBook

## CLINICAL GENE TRANSFER: STATE-OF-THE-ART

Edited by  
**ODILE COHEN-HAGUENAUER**





*« Hope lies in dreams, in imagination and in the courage  
of those who dare to make dreams into reality »*  
Jonas Salk, 1914-1995

*« The joys of science lie in the work itself;  
the ultimate reward being the progress of mankind »*  
Rosalind Elsie Franklin, 1920-1958

*« The utmost limitations in science and discovery are not  
at the frontiers and complexity of research but in people's minds:  
it's all about keeping the faith ... »*

à Julien, Antoine et Paul

# CliniGene Partners and Boards

## **CLINIGENE ACTING PARTNERS**

### • Academic partners

**ALESSANDRO AIUTI (and EUGENIO MONTINI)**, *FCSR-TIGET, San Raffaele Telethon Institute for Gene Therapy, Milan, Italy; Medical Genetics, Department of Pediatrics, “Federico II” University, Naples, Italy.*

**ROBIN R. ALI**, *Institute of Ophthalmology, UCL, London, England.*

**ALBERTO AURICCHIO**, *Telethon Institute of Genetics and Medicine, FTELE-IGM, Napoli, Italy.*

**SÉGOLÈNE AYMÉ**, *Orphanet, Inserm SC11, Plate-forme Maladies Rares, Paris, France.*

**CHRISTOPHER BAUM (and TONI CATHOMEN<sup>1</sup>)**, *Medizinische Hochschule Hannover, MHH, Hannover, Germany.*

**FATIMA BOSCH**, *CBATEG-UAB, Universitat Autònoma de Barcelona, Barcelona, Spain.*

**JAN BUBENIK - MILAN REINIS**, *Institute of Molecular Genetics, IMG CAS, Prague, Czech Republic.*

**NATHALIE CARTIER**, *Inserm UMR 745, University Paris-Descartes, Sorbonne Paris-Cité, Paris, France.*

**KLAUS CICHUTEK (and MATTHIAS SCHWEIZER)**, *Paul-Ehrlich-Institut, PEI, Langen, Germany.*

**MANUEL J.T. CARRONDO (and PEDRO E. CRUZ)**, *Instituto de Biologia Experimental e Tecnologica, IBET-ITBQ, Oeiras, Portugal.*

**NICOLE DÉGLON**, *MIRCEM, Commissariat à l'Énergie Atomique-CEA, Saclay, France.<sup>2</sup>*

**GEORGES DICKSON (and RAFAEL J. YÁÑEZ-MUÑOZ)**, *School of Biological Sciences, Royal Holloway-University of London (RHUL), Egham, Surrey, United Kingdom*

**MARK FEDERSPIEL - STEPHEN J. RUSSELL**, *Gene Therapy Program, Mayo Clinic College of Medicine, Rochester, USA.*

**GÖSTA GAHRTON**, *Department of Medicine, Karolinska Institutet-KI, Stockholm, Sweden.*

**BERND GÄNSBACHER**, *Institute of Experimental Oncology and Therapy Research, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany.*

**MAURO GIACCA**, *International Centre for Genetic Engineering and Biotechnology, ICGEB, Trieste, Italy.<sup>3</sup>*

<sup>1</sup>Now at Laboratory of Cell and Gene Therapy, University Medical Center Freiburg, Engesserstr. 4, D-79108 Freiburg, Germany.

<sup>2</sup>Now at Laboratory of Cellular and Molecular Neurotherapies, Lausanne University Medical School (CHUV), Lausanne, Switzerland.

<sup>3</sup>A CliniGene-SAB member until 2010.

**HANSJÖRG HAUSER (and DAGMAR WIRTH)**, *The Helmholtz Centre for Infection Research-HZI, Braunschweig, Germany.*

**ZSUZSANNA IZSVAK**, *Max Delbrück Center for Molecular Medicine, MDC, Berlin, Germany.*

**ANDREAS H. JACOBS**, *Laboratory for Gene Therapy and Molecular Imaging at the Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch-Laboratories of the Max Planck Society and the Faculty of Medicine of the University of Cologne, Cologne, Germany; European Institute for Molecular Imaging (EIMI), University of Münster (WWU) Münster, Germany; Department of Geriatric Medicine, Johanniter Hospital, Bonn, Germany. [ahjacobs@uni-muenster.de](mailto:ahjacobs@uni-muenster.de)*

**CHRISTOF VON KALLE (and MANFRED SCHMIDT)**, *National Center for Tumor Diseases, NCT and German Cancer Research Center, DKFZ, Heidelberg, Germany.*

**DAVID KLATZMANN**, *Immunologie-Immunopathologie-Immunothérapie, Assistance Publique-Hopitaux de Paris (APHP), CNRS UMR7211 and Inserm U959, CERVI, Hôpital Pitié-Salpêtrière, Paris, France.*

**STEFAN KOCHANEK**, *University of Ulm, Ulm, Germany.*

**OTTO-WILHELM MERTEN - FULVIO MAVILIO (CSO) - FRÉDÉRIC REVAH (CEO)**, *Généthon, Évry, France.<sup>4,5</sup>*

**NICOLAS MERMOD**, *Institut de Biotechnologie, UNIL, Lausanne, Switzerland.*

**LLUIS MIR**, *UMR 8121 CNRS, Institut Gustave-Roussy, Villejuif, France.*

**PHILIPPE MOULLIER**, *CHU de Nantes, Laboratoire de Thérapie Génique, Inserm UMR649, Faculté de Médecine et Université, Nantes, France.<sup>4</sup>*

**AMOS PANET**, *Institute for Medical Research, Hebrew University, Hadassah Medical School-HUJI, Jerusalem, Israel.*

**MARC PESCHANSKI**, *I-STEM, Inserm UEVE 861, AFM, 5, rue Henri-Desbrùères, 91030 Évry Cedex, France.*

**DANIEL SCHERMAN**, *Inserm U1022, CNRS UMR 8151, Faculté de Pharmacie, Université Paris Descartes, Sorbonne Paris-Cité, Paris, France; Chimie Paris Tech, Paris, F-75005, France.*

**THIERRY VANDENDRIESCHE**, *Division of Gene Therapy and Regenerative Medicine, Free University of Brussels-VUB, Brussels, Belgium.*

**SEPPO YLÄ-HERTTUALA**, *A.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland*

**and ODILE COHEN-HAGUENAUER**, *CliniGene-NoE coordinator, École Normale Supérieure de Cachan, CNRS UMR 8113; and Oncogenetics, Department of Clinical Oncology, Hôpital Saint-Louis AP-HP; Faculté de Médecine, Université Paris-Diderot, Sorbonne Paris-Cité, 75475 Paris Cedex 10, France.*

<sup>4</sup> Anne-Marie Masquelier was CEO of Généthon from 2005 to 2008.

<sup>5</sup> Philippe Moullier was CSO of Généthon from 2009 to 2011.



## • Industry partners

**PEDRO E. CRUZ**, *ECBio-Investigação e Desenvolvimento em Biotecnologia, S.A., Amadora, Portugal.*

**CHARLOTTE DALBA**, *Epixis, Paris-Lyon, France.*<sup>6</sup>

**FRÉDÉRIC HENRY**, *CleanCells, Boufféré (Nantes), France.*

**SOPHIE LABEL-BINAY**, *Bioalliance Pharma SA, Paris, France.*

**MONIKA LUSKY - JEAN-YVES BONNEFOY**, *Transgene SA, Strasbourg, France.*

**KYRIACOS MITROPHANOUS**, *Oxford BioMedica (UK) Ltd., Oxford, United Kingdom.*

**FELICIA M. ROSENTHAL**, *CellGenix Technologie Transfer GmbH, Freiburg, Germany.*

**MARTIN SCHLEEF**, *PlasmidFactory GMBH and CO. KG, Bielefeld, Germany.*

**MARTIN WISHER**, *Bioreliance Ltd, Stirling, United Kingdom.*

**OLIVIER ZELPHATI**, *OZ Biosciences SAS-OZB, Marseille, France.*

**VINCENT ZULIANI**, *Genosafe SAS, Évry, France.*

## **CLINIGENE SCIENTIFIC ADVISORY BOARD**

**LUCIO LUZZATTO (Chair)**, *Honorary Professor of Haematology, University of Firenze; Scientific Director, Istituto Toscano Tumori, Via Taddeo Alderotti 26N, 50139 Firenze, Italy.*

**MAURO GIACCA**, *ICGEB, Trieste, Italy.*<sup>7</sup>

**GABRIEL MERGUI**, *Genopole® IDF, Évry, France.*

**TIMOTHY O'BRIEN**, *REMEDI, University of Galway, Galway, Ireland.*

**MONIKA PREUSS**, *Genetics Science Safety and Regulation, Scientific Development and Bioethics Division, Department of Health, London, United Kingdom.*

**LEN SEYMOUR**, *Oxford University and Hospital, Oxford, United Kingdom.*

## **CLINIGENE INTERNATIONAL BOARD**

**INDER M. VERMA (Chair)**, *Laboratory of Genetics, The Salk Institute, La Jolla, CA, USA.*

**MICHAEL BLAESE**, *Institute for Inherited Disease Research, Princeton, Newtown, PA, USA.*

**MICHELE LIPUCCI DI PAOLA**, *EURORDIS, Paris, France.*<sup>8</sup>

**JACQUELINE CORRIGAN-CURAY**, *Acting Director, NIH-OBA RAC, Bethesda, MA, USA.*

**TED FRIEDMANN**, *University of California at San Diego-UCSD, San Diego, CA, USA.*

<sup>6</sup> Epixis now at VBI, France-USA.

<sup>7</sup> Advisory Board from 2006 to 2010, Partner from 2010 on.

<sup>8</sup> And formerly Fabrizia Bignami, now at GSK rare diseases.

**KATHERINE HIGH**, *The Children's Hospital of Philadelphia-CHOP, Philadelphia, PA, USA.*

**ALASTAIR KENT**, *Genetic Alliance UK, London, United Kingdom.*

**NANCY M.P. KING**, *Wake Forest University School of Medicine, Winston Salem, NC, USA.*

**MICHEL MARTY**, *CITOH-APHP Hôpital Saint-Louis and EuroCancer, Paris, France.*

**PAUL ROBBINS**, *University of Pittsburgh School of Medicine, Molecular Genetics and Biochemistry, Pittsburgh, PA, USA.*

**MICHEL SADELAIN**, *Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering, Cancer Center, New York, NY, USA.*

**RICHARD SNYDER**, *Center of Excellence for Regenerative Health Biotechnology (CERHB), University of Florida (UF), Gainesville, FL, USA.*

**DANIEL TAKEFMAN - CAROLYN WILSON - VICTOR XIAOBIN LU**, *FDA-CBER, Rockville, MA, USA.*

**JEAN-HUGUES TROUVIN**, *AGEPS AP-HP ANSM and EMA-CHMP-BWP, Paris, France.*

**NICOLE ZERNIK**, *President, Europa-Donna Forum France, Paris, France.*

### ***CLINIGENE ETHICAL REVIEW BOARD***

**ALASTAIR KENT (Chair)**, *member of the International Board.*

**NANCY M.P. KING (Vice-Chair)**, *member of the International Board.*

**ALESSANDRO AIUTI**, *partner.*

**FABRIZIA BIGNAMI**, *former member of the Scientific Advisory Board.*

**KLAUS CICHUTEK**, *partner.*

**ODILE COHEN-HAGUENAUER**, *coordinator.*

**GÖSTA GAHRTON**, *partner.*

**MICHELE LIPUCCI DI PAOLA**, *member of the Scientific Advisory Board.*

**LUCIO LUZZATTO**, *chair of the Scientific Advisory Board.*

**MONIKA PREUSS**, *member of the Scientific Advisory Board.*

### ***CLINIGENE ASSOCIATE MEMBERS***

**ERIC ALTON and UTA GRIESENBACH**, *UK Cystic Fibrosis Gene Therapy Consortium, Imperial College London, London, United Kingdom.*

**CORINNE AUGÉ-GOUILLOU**, *CNRS - University of Tours, Tours, France.*

**BAS BLITS**, *NL Institute for Neurosciences and AMT (now UniQure), Amsterdam, The Netherlands.*

**PITER BOSMA**, *Gaubius Institute for Cardiovascular Research of TNO, Leiden, The Netherlands.*

**MARY COLLINS**, *University College of London, London, United Kingdom.*

**OLIVIER DANOS**, *Necker Hospital CNRS and UCL-UK (now, NYC, USA).*

**JEAN-LUC DARLIX**, *École Normale Supérieure de Lyon, Lyon, France.*

**JANE FARRAR**, *University College Cork, Cork, Ireland.*

**JÜRGEN KLEINSCHMIDT**, *DKFZ, Heidelberg, Germany.*

**BERNARD MASSIE**, *University of Montreal, Montreal, Canada.*

**AMIT NATHWANI**, *Haematology, Cancer, University College London Hospitals, London, United Kingdom.*

**MARC SITBON**, *IGMM, CNRS-Inserm, Université de Montpellier 2, Montpellier, France.*

**MICHAEL THEMIS**, *Imperial College London, London, United Kingdom.*



## WITH THE EDITOR'S SPECIAL THANKS TO:

- *Fernand Sauer and Octavi Quintana-Trias, for their thrilling vision of the European research area and advancement of progress in Human Health,*
- *Mario Capecchi and Bob Weinberg for triggering deep inspiration and perseverance,*
- *Paul Janiaud for sharing his magical views and unlimited enthusiasm,*
- *Wonderful colleagues of the Euregenethy EC-DG research network [Fatima Bosch, Pedro Cruz, Manuel Carrondo, Klaus Cichutek, Nicole Déglon, George Dickson, Bernd Gänsbacher, Gösta Gahrton, Luigi Naldini, Felicia Rosenthal, Seppo Ylä-Herttuala], together with Christian Auclair, Stephen J. Russell, Lucio Luzzatto, Inder Verma, Gabriel Mergui, Pierre Tambourin, Ted Friedmann and our late friend Ketty Schwartz who placed trust in the initiation of the CliniGene-NoE,*
- *Fatiha Sadallah, Arnd Hoeverler, Brigitte Sambain, Jean-Emmanuel Faure, Gérard Rivières and Jacques Demotes,*
- *Jacqueline Corrigan-Curay and Allan Shipp for fruitful interaction,*
- *Celia Tunc and Nicolas Creff, the two main CliniGene managers who gave graceful everyday life to our endeavour with special dedication and to Michel Profeta,*
- *The amazingly gifted young trainees - acting as professionals - of the NSIGMA (ENSIMAG, Grenoble, 2006) and ESCP Europe Conseil (ESCP-Europe, Paris, 2010) junior enterprises who produced our dedicated CliniSoft scientific and strategic software and the CliniGene Strategic-Business Plan, respectively,*
- *Caroline Duros, Alexandre Artus for shared jubilation and high fidelity,*
- *Dr Marc Espié, for his patience, generosity, humanism and faithful support,*
- *The whole administrative staff of the École Normale Supérieure de Cachan and its former President, Jean-Yves Mérindol,*
- *Marc Sitbon and Jean-Michel Heard for pivotal initial training,*
- *Isabelle Benoit and Christian Grenaudier, for sharing style with science,*
- *EDK Publisher, in particular the lovely and smart Martine Krief and François Flori, acting as a magician,*
- *Enlightened Cloro who gave me birth twice and took us to have faith in whatever would be done, should be for love.*

*It's all about keeping the faith, hope and turn dreams into reality  
O.C.H.*



# List of authors

## **ALESSANDRO AIUTI**

San Raffaele Telethon Institute for Gene Therapy, Milan, Italy; Department of Pediatrics, University of Rome Tor Vergata, Children's Hospital Bambino Gesù, Rome, Italy. [a.aiuti@hsr.it](mailto:a.aiuti@hsr.it)

## **ROBIN R. ALI**

UCL Institute of Ophthalmology, Department of Genetics, 11-43 Bath Street, London EC1V 9EL, United Kingdom. [r.ali@ucl.ac.uk](mailto:r.ali@ucl.ac.uk)

## **EVREN ALICI**

Cell and gene therapy center, department of medicine, division of hematology, Karolinska Institutet, Karolinska University Hospital, Huddinge, Sweden.

## **PER ALMQVIST**

Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden;  
Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden.

## **PATRIZIA ANNUNZIATA**

Telethon Institute of Genetics and Medicine (TIGEM), Naples, Italy; Medical Genetics, Department of Pediatrics, Federico II University, Naples, Italy.

## **MARTINA ANTON**

Institute of Experimental Oncology and Therapy Research, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany.

## **ALEXANDRE ARTUS**

CNRS UMR 8113 and CliniGene, École Normale Supérieure de Cachan, 94235 Cachan, France.

## **TAKIS ATHANASOPOULOS**

School of Biological Sciences, Royal Holloway, University of London, Egham Hill, Egham, Surrey, TW20 0EX, United Kingdom.

## **PATRICK AUBOURG**

Inserm UMR 745, University Paris Descartes, Sorbonne Paris-Cité, 75279, Paris, France; Department of Pediatric Endocrinology and Neurology, Hôpital de Bicêtre, 94275 Le Kremlin-Bicêtre, France.

## **GWENNAELLE AUREGAN**

CEA, Institute of Biomedical Imaging (I2BM) and Molecular Imaging Research Center (MIRCen), Fontenay-aux-Roses, France; CNRS-CEA URA2210, Fontenay-aux-Roses, France.

## **ALBERTO AURICCHIO**

Telethon Institute of Genetics and Medicine (TIGEM), Naples, Italy; Medical Genetics, Department of Pediatrics, "Federico II" University, Naples, Italy. [auricchio@tigem.it](mailto:auricchio@tigem.it)

**EDUARD AYUSO**

Center of Animal Biotechnology and Gene Therapy and Department of Biochemistry and Molecular Biology, School of Veterinary Medicine, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain. CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Spain. [eduard.ayuso@uab.es](mailto:eduard.ayuso@uab.es)

**VANESSA BANDEIRA**

IBET, Apartado 12, 2781-901 Oeiras, Portugal.

**RITA N. BÁRCIA**

ECBio, S.A., R. Henrique Paiva Couceiro, 27, 2700-451 Amadora, Portugal.

**CYNTHIA C. BARTHOLOMAE**

National Center for Tumor Diseases and German Cancer Research Center, 69120 Heidelberg, Germany.

**CHRISTOPHER BAUM**

Hannover Medical School (MHH) Institute of Experimental Haematology, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany. [baum.christopher@mh-hannover.de](mailto:baum.christopher@mh-hannover.de)

**ÉMILIE BAYART**

CNRS UMR 8113 and CliniGene, École Normale Supérieure de Cachan, 94235 Cachan, France.

**CHRISTIEN BEDNARSKI**

Laboratory of Cell and Gene Therapy, Center for Chronic Immunodeficiency, University Medical Center Freiburg, Engesserstr. 4, D-79108 Freiburg, Germany.

**BERTRAND BELLIER**

UPMC Université Paris 06, CNRS, UMR 7211, Inserm, U959, Bâtiment CERVI, Hôpital Pitié-Salpêtrière, 83, boulevard de l'Hôpital, F-75013 Paris, France.

**LUCA BIASCO**

San Raffaele Telethon Institute for Gene Therapy, Milano, Italy; Università Vita-Salute San Raffaele, Milano, Italy.

**PASCAL BIGEY**

CNRS, UMR8151, Inserm, U1022, Université Paris Descartes, Sorbonne Paris Cité, Faculté de Pharmacie, Chemical and Genetic Pharmacology and Imaging Laboratory, Paris, F-75270 France; École Nationale Supérieure de Chimie de Paris, Chimie ParisTech, Paris, F-75005 France.

**VÉRONIQUE BLOUIN**

CHU de Nantes, Faculté de Médecine, Université de Nantes, Nantes, France.

**JUERGEN BODE**

Hannover Medical School (MHH), Institute of Experimental Haematology, OE 6960, D-30625 Hannover, Germany. [bode.juergen@mh-hannover.de](mailto:bode.juergen@mh-hannover.de)

**GILLES BONVENTO**

CEA, Institute of Biomedical Imaging (I2BM) and Molecular Imaging Research Center (MIRcen), Fontenay-aux-Roses, France; CNRS-CEA URA2210, Fontenay-aux-Roses, France.



**FATIMA BOSCH**

Center of Animal Biotechnology and Gene Therapy and Department of Biochemistry and Molecular Biology, School of Veterinary Medicine, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain. CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Spain. [fatima.bosch@uab.es](mailto:fatima.bosch@uab.es)

**PIERRE BOUGNÈRES**

Department of Pediatric Endocrinology and Neurology, Hôpital de Bicêtre, 94275 Le Kremlin-Bicêtre, France.

**IMMACOLATA BRIGIDA**

San Raffaele Telethon Institute for Gene Therapy, Milan, Italy.

**SANDRA BROLL**

Helmholtz Centre for Infection Research (HZI), Department Mol Biotech, Braunschweig, Germany.

**CHRISTIAN J. BUCHHOLZ**

Division of Medical Biotechnology, Paul-Ehrlich-Institut, Langen, Germany.

**MICHEL-FRANCIS BUREAU**

CNRS, UMR8151, Paris, F-75006 France; Inserm, U1022, Université Paris Descartes, Sorbonne Paris-Cité, Faculté de Pharmacie, Chemical and Genetic Pharmacology and Imaging Laboratory, Paris, F-75270 France; École Nationale Supérieure de Chimie de Paris, Chimie ParisTech, Paris, F-75005 France.

**DAVID CALLEJAS**

Center of Animal Biotechnology and Gene Therapy and Department of Biochemistry and Molecular Biology, School of Veterinary Medicine, Universitat Autònoma de Barcelona, 08193-Bellaterra, and CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Spain.

**MANUEL J.T. CARRONDO**

Instituto de Tecnologia Química e Biológica-Universidade Nova de Lisboa/Instituto de Biologia Experimental e Tecnológica (ITQB-UNL/IBET), P-2781-901 Oeiras, Portugal; Faculdade de Ciências e Tecnologia/Universidade Nova de Lisboa (FCT/UNL), P-2825 Monte da Caparica, Portugal.

**NATHALIE CARTIER**

Inserm U745, Faculty of Pharmaceutical Sciences, Paris Descartes University, Sorbonne Paris-Cité, 4, avenue de l'Observatoire, 75006, Paris, France; Department of Pediatric Endocrinology and Neurology, Hôpital de Bicêtre, 94275 Le Kremlin-Bicêtre, France. [nathalie.cartier@inserm.fr](mailto:nathalie.cartier@inserm.fr)

**TONI CATHOMEN**

Laboratory of Cell and Gene Therapy, Center for Chronic Immunodeficiency, University Medical Center Freiburg, Engesserstr. 4, D-79108 Freiburg, Germany. [toni.cathomen@uniklinik-freiburg.de](mailto:toni.cathomen@uniklinik-freiburg.de)

**MARINA CAVAZZANA-CALVO**

Department of Biotherapy, Hôpital Necker-Enfants Malades, 75743 Paris, France;  
Inserm UMR768, University Paris-Descartes, Sorbonne Paris-Cité, 75743 Paris, France;  
Clinical Investigation Center in Biotherapy, Groupe Hospitalier Universitaire Ouest,  
75743 Paris, France.

**MARINEE K.L. CHUAH**

Department of Gene Therapy and Regenerative Medicine, Free University of Brussels  
(VUB), Faculty of Medicine and Pharmacy, University Medical Center - Jette,  
Laarbeeklaan 103, B-1090 Brussels, Belgium; Department of Molecular Cardiovascular  
Medicine, University of Leuven, University Hospital Campus Gasthuisberg, Belgium.  
[marinee.chuah@vub.ac.be](mailto:marinee.chuah@vub.ac.be)

**KLAUS CICHUTEK**

President, Paul-Ehrlich-Institut, Paul-Ehrlich-Straße 51-59, 63225 Langen, Germany.  
[cickl@pei.de](mailto:cickl@pei.de)

**ODILE COHEN-HAGUENAUER**

École Normale Supérieure de Cachan, CliniGene, CNRS UMR 8113, 94235 Cachan;  
and Department of Medical Oncology, Hôpital Saint-Louis AP-HP; Faculté de  
Médecine, University Paris7-Diderot, Sorbonne-Paris-Cité, 75475 Paris Cedex 10, France.  
[odile.cohen@lbpa.ens-cachan.fr](mailto:odile.cohen@lbpa.ens-cachan.fr)

**ANGÉLIQUE COLIN**

CEA, Institute of Biomedical Imaging (I2BM) and Molecular Imaging Research Center  
(MIRCent), Fontenay-aux-Roses, France; CNRS-CEA URA2210, Fontenay-aux-Roses,  
France.

**GONZALO CORDOVA**

CNRS, UMR8151, Paris, F-75006 France; Inserm, U1022, Université Paris Descartes,  
Sorbonne Paris-Cité, Faculté de Pharmacie, Chemical and Genetic Pharmacology and  
Imaging Laboratory, Paris, F-75270 France; École Nationale Supérieure de Chimie de  
Paris, Chimie ParisTech, Paris, F-75005 France.

**ANA SOFIA COROADINHA**

Instituto de Tecnologia Química e Biológica-Universidade Nova de Lisboa/Instituto de  
Biologia Experimental e Tecnológica (ITQB-UNL/IBET), P-2781-901 Oeiras, Portugal.  
[avalente@itqb.unl.pt](mailto:avalente@itqb.unl.pt)

**FRANÇOIS-LOÏC COSSET**

École Normale Supérieure de Lyon; Inserm, U758, Human Virology laboratory, EVIR  
Team; University of Lyon, UCB-Lyon1, Lyon, F-69007, France. [flcosset@ens-lyon.fr](mailto:flcosset@ens-lyon.fr)

**GABRIELLA COTUGNO**

Telethon Institute of Genetics and Medicine (TIGEM), Naples, Italy; Medical Genetics,  
Department of Pediatrics, “Federico II” University, Naples, Italy.

**PEDRO E. CRUZ**

Instituto de Tecnologia Química e Biológica-Universidade Nova de Lisboa/Instituto de  
Biologia Experimental e Tecnológica (ITQB-UNL/IBET), P-2781-901 Oeiras, Portugal;  
ECBio, S.A., P-2700-451 Amadora, Portugal. [pcruz@itqb.unl.pt](mailto:pcruz@itqb.unl.pt)

**HELDER J.S. CRUZ**

ECBio, S.A., R. Henrique Paiva Couceiro, 27, 2700-451 Amadora, Portugal.

**CHRISTOPHE DARMON**

CHU de Nantes, Faculté de Médecine, Université de Nantes, Nantes, France; EFS-Atlantic Bio GMP, Saint-Herblain, France.

**ANDREW M. DAVIDOFF**

Department of Surgery, St. Jude Children's Research Hospital, Memphis, TN, USA.

**NICOLE DÉGLON**

CEA, Institute of Biomedical Imaging (I2BM) and Molecular Imaging Research Center (MIRCen), Fontenay-aux-Roses, France; CNRS-CEA URA2210, Fontenay-aux-Roses, France; **Present address:** Centre Hospitalier Universitaire Vaudois (CHUV), Département des Neurosciences Cliniques, Laboratoire de Neurothérapies Cellulaires et Moléculaires, Pavillon 3, Avenue de Beaumont, 1011 Lausanne, Suisse.  
[nicole.deglon@chuv.ch](mailto:nicole.deglon@chuv.ch)

**GEORGE DICKSON**

School of Biological Sciences, Royal Holloway, University of London, Egham Hill, Egham, Surrey, TW20 0EX, United Kingdom. [g.dickson@rhul.ac.uk](mailto:g.dickson@rhul.ac.uk)

**KURT E.J. DITTMAR**

Department of Gene Regulation and Differentiation, Helmholtz Centre for Infection Research (HZI), Inhoffenstr. 7, D-38124 Braunschweig, Germany.

**RUXANDRA DRAGHIA-AKLI**

MD, PhD, RTD-Director Health, Research and Innovation DG European Commission, B - 1049 Brussels, Belgium. [ruxandra.draghia-akli@ec.europa.eu](mailto:ruxandra.draghia-akli@ec.europa.eu)

**NOËLLE DUFOUR**

CEA, Institute of Biomedical Imaging (I2BM) and Molecular Imaging Research Center (MIRCen), Fontenay-aux-Roses, France; CNRS-CEA URA2210, Fontenay-aux-Roses, France.

**LYDIA DÜRNER**

Pharma Research and Early Development, Roche Glycart AG, CH-8952 Schlieren, Switzerland.

**CAROLINE DUROS**

CNRS UMR 8113 and CliniGene, École Normale Supérieure de Cachan, 94235 Cachan, France.

**MARIA ERIKSDOTTER-JÖNHAGEN**

Department of Neurobiology, Caring Sciences and Society, Division of Clinical Geriatrics, Karolinska Institutet and Karolinska University Hospital, Huddinge, Novum, Plan 5, SE-141 86, Stockholm, Sweden; Department of Geriatrics, Karolinska University Hospital, Stockholm, Sweden. [maria.eriksdotter.jonhagen@ki.se](mailto:maria.eriksdotter.jonhagen@ki.se)

**CAROLE ESCARTIN**

CEA, Institute of Biomedical Imaging (I2BM) and Molecular Imaging Research Center (MIRCent), Fontenay-aux-Roses, France; CNRS-CEA URA2210, Fontenay-aux-Roses, France.

**VIRGINIE ESCRIOU**

CNRS, UMR8151, Paris, F-75006 France; Inserm, U1022, Université Paris Descartes, Sorbonne Paris Cité, Faculté de Pharmacie, Chemical and Genetic Pharmacology and Imaging Laboratory, Paris, F-75270 France; École Nationale Supérieure de Chimie de Paris, Chimie ParisTech, Paris, F-75005 France.

**HELGA EYJOLFSDOTTIR**

Department of Neurobiology, Caring Sciences and Society, Division of Clinical Geriatrics, Karolinska Institutet, Sweden; Department of Geriatrics, Karolinska University Hospital, Stockholm, Sweden.

**MATHILDE FAIDEAU**

CEA, Institute of Biomedical Imaging (I2BM) and Molecular Imaging Research Center (MIRCent), Fontenay-aux-Roses, France; CNRS-CEA URA2210, Fontenay-aux-Roses, France.

**HELEN FOSTER**

School of Biological Sciences, Royal Holloway, University of London, Egham Hill, Egham, Surrey, TW20 0EX, United Kingdom.

**KEITH FOSTER**

School of Biological Sciences, Royal Holloway, University of London, Egham Hill, Egham, Surrey, TW20 0EX, United Kingdom.

**ALAIN FISCHER**

Inserm UMR768, University Paris-Descartes, Sorbonne Paris-Cité et Service d'Immuno-Hématologie, Hôpital Necker-Enfants Malades, 75743 Paris, France.

**GÖSTA GAHRTON**

Karolinska Institutet, Department of Medicine, Karolinska University Hospital, Huddinge, SE 14186 Stockholm, Sweden. [gosta.gahrton@ki.se](mailto:gosta.gahrton@ki.se)

**MELANIE GALLA**

Hannover Medical School (MHH) Institute of Experimental Haematology, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany.

**ANNE GALY**

Inserm U951 and Généthon, 1, rue de l'Internationale, BP60, F-91002 Évry Cedex, France.

**LEONOR GAMA-NORTON**

Instituto de Tecnologia Química e Biológica-Universidade Nova de Lisboa/Instituto de Biologia Experimental e Tecnológica (ITQB-UNL/IBET), P-2781-901 Oeiras, Portugal; Helmholtz Centre for Infection Research, D-38124 Braunschweig, Germany.

**BERND GÄNSBACHER**

Institute of Experimental Oncology and Therapy Research, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany. [bernd.gansbacher@lrz.tum.de](mailto:bernd.gansbacher@lrz.tum.de)

**HENK S.P. GARRITSEN**

Institute for Clinical Transfusion Medicine, Städtisches Klinikum Braunschweig gGmbH, Braunschweig, Germany.

**ANASTASIOS GEORGIADIS**

UCL Institute of Ophthalmology, Department of Genetics, 11-43 Bath Street, London EC1V 9EL, United Kingdom.

**MAURO GIACCA**

Molecular Medicine Laboratory, International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 99, 34149 Trieste, Italy. [giacca@icgeb.org](mailto:giacca@icgeb.org)

**MARI GILLJAM**

Cell and gene therapy center, department of medicine, division of hematology, Karolinska Institutet, Karolinska University Hospital, Huddinge, Sweden.

**SALIMA HACEIN-BEY-ABINA**

Department of Biotherapy, Hôpital Necker-Enfants Malades, 75743 Paris, France; Inserm UMR768, University Paris-Descartes, Sorbonne Paris-Cité, 75743 Paris, France; Clinical Investigation Center in Biotherapy, Groupe Hospitalier Universitaire Ouest, 75743 Paris, France.

**EVA-MARIA HÄNDEL**

Institute of Experimental Hematology, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany.

**PHILIPPE HANTRAYE**

CEA, Institute of Biomedical Imaging (I2BM) and Molecular Imaging Research Center (MIRCent), Fontenay-aux-Roses, France; CNRS-CEA URA2210, Fontenay-aux-Roses, France.

**MARK HASKINS**

Departments of Patho- biology and Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA.

**RAYMONDE HASSIG**

CEA, Institute of Biomedical Imaging (I2BM) and Molecular Imaging Research Center (MIRCent), Fontenay-aux-Roses, France; CNRS-CEA URA2210, Fontenay-aux-Roses, France.

**HANSJÖRG HAUSER**

Department of Gene Regulation and Differentiation, Helmholtz-Zentrum für Infektionsforschung, Inhoffenstr. 7, D-38124 Braunschweig, Germany. [hha@helmholtz.de](mailto:hha@helmholtz.de)

**NIELS HEINZ**

Hannover Medical School (MHH), Institute of Experimental Haematology, OE 6960, D-30625 Hannover, Germany.

**ZOLTÁN IVICS**

Max Delbrück Centrum for Molecular Medicine, Robert Rossle Strasse 10, Berlin D-13122, Germany

**ZSUZSANNA IZSVÁK**

Max Delbrück Centrum for Molecular Medicine, Robert Rossle Strasse 10, Berlin D-13122, Germany; [zizsvak@mdc-berlin.de](mailto:zizsvak@mdc-berlin.de)

**ANDREAS H. JACOBS**

<sup>1</sup>Laboratory for Gene Therapy and Molecular Imaging at the Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch-Laboratories of the Max Planck Society and the Faculty of Medicine of the University of Cologne, Cologne, Germany;

<sup>2</sup>European Institute for Molecular Imaging (EIMI), University of Münster (WWU), Münster, Germany; <sup>3</sup>Department of Geriatric Medicine, Johanniter Hospital, Bonn, Germany. [ahjacobs@uni-muenster.de](mailto:ahjacobs@uni-muenster.de)

**SUSAN JARMIN**

School of Biological Sciences, Royal Holloway, University of London, Egham Hill, Egham, Surrey, TW20 0EX, United Kingdom.

**VERONICA JIMENEZ**

Center of Animal Biotechnology and Gene Therapy and Department of Biochemistry and Molecular Biology, School of Veterinary Medicine, Universitat Autònoma de Barcelona, 08193-Bellaterra, and CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Spain.

**CHRISTOF VON KALLE**

National Center for Tumor Diseases NCT and German Cancer Research Center DKFZ, 69120 Heidelberg, Germany.

**JAGJEET KANG**

School of Biological Sciences, Royal Holloway, University of London, Egham Hill, Egham, Surrey, TW20 0EX, United Kingdom.

**ALASTAIR KENT**

Genetic Alliance UK, Unit 4D, Leroy House, 436 Essex Road, London N1 3QP, United Kingdom.

**ABED KHALAILEH**

Departments of Biochemistry and Surgery, the Hebrew University-Hadassah Medical School, IMRIC, Jerusalem, Israel.

**ANTOINE KICHLER**

CNRS, UMR8151, Paris, F-75006 France; Inserm, U1022, Université Paris Descartes, Sorbonne Paris Cité, Faculté de Pharmacie, Chemical and Genetic Pharmacology and Imaging Laboratory, Paris, F-75270 France; École Nationale Supérieure de Chimie de Paris, Chimie ParisTech, Paris, F-75005, France.

**NANCY M.P. KING**

JD, Professor, Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Co-Director, WFU Center for Bioethics, Health, and Society, Wells Fargo 14, Medical Center Boulevard, Winston-Salem, NC 27157, USA.

**DAVID KLATZMANN**

UPMC Université Paris 06, CNRS, UMR 7211, Inserm, U959, Bâtiment CERVI, Hôpital Pitié-Salpêtrière, 83, boulevard de l'Hôpital, F-75013 Paris, France.  
[david.klatzmann@upmc.fr](mailto:david.klatzmann@upmc.fr)

**STEFAN KOCHANEK**

Department of Gene Therapy, University of Ulm, Helmholtz Str. 8/1, 89081 Ulm, Germany. [stefan.kochanek@uni-ulm.de](mailto:stefan.kochanek@uni-ulm.de)

**DROR KOLODKIN-GAL**

Departments of Biochemistry and Surgery, the Hebrew University-Hadassah Medical School, IMRIC, Jerusalem, Israel.

**TAEYOUNG KOO**

School of Biological Sciences, Royal Holloway, University of London, Egham Hill, Egham, Surrey, TW20 0EX, United Kingdom.

**NIKOLAI KUNICHER**

Departments of Biochemistry and Surgery, the Hebrew University-Hadassah Medical School, IMRIC, Jerusalem, Israel.

**KRISTINA LACHMANN**

Fraunhofer-Institut für Schicht- und Oberflächentechnik (IST), Braunschweig, Germany.

**STEPHANIE LAUFS**

Department of Translational Oncology, National Center for Tumor Diseases NCT and German Cancer Research Center (DKFZ), Heidelberg, Germany.

**STÉPHANIE LEMAIRE**

CNRS UMR 8113 and CliniGene, École Normale Supérieure de Cachan, 94235 Cachan, France.

**FRANÇOIS LEMOINE**

Université Pierre et Marie Curie, UPMC Université Paris 06, CNRS UMR7211, Inserm U959, Clinical Investigation Center in Biotherapy, AP-HP, Hôpital Pitié-Salpêtrière, F-75651, Paris 13, France.

**GÖRAN LIND**

Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden;  
Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden.

**WERNER LINDENMAIER**

Department of Gene Regulation and Differentiation, Helmholtz Centre for Infection Research (HZI), Inhoffenstr. 7, D-38124 Braunschweig, Germany.  
[werner.lindenmaier@helmholtz-hzi.de](mailto:werner.lindenmaier@helmholtz-hzi.de)

**BENGT LINDEROTH**

Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden;  
Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden.

**MARTIN LOCK**

Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, USA.

**TANJA LUCAS**

Department of Gene Therapy, University of Ulm, Helmholtz Str. 8/1, 89081 Ulm, Germany.

**LUCIO LUZZATTO**

Honorary Professor of Haematology, University of Firenze; Scientific Director, Istituto Toscano Tumori, Via Taddeo Alderotti 26N, 50139 Firenze, Italy.

[lucio.luzzatto@ittumori.it](mailto:lucio.luzzatto@ittumori.it)

**LARS MACKE**

Department of Molecular Biotechnology, Helmholtz Centre for Infection Research (HZI), Inhoffenstr. 7, Institute for Clinical Transfusion Medicine, Städtisches Klinikum Braunschweig gGmbH, D-38124 Braunschweig, Germany.

**TOBIAS MAETZIG**

Hannover Medical School (MHH) Institute of Experimental Haematology, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany.

**THOMAS MALDINEY**

Unité de Pharmacologie Chimique et Génétique et d'Imagerie; CNRS, UMR 8151, Inserm, U 1022, Université Paris Descartes, Sorbonne Paris-Cité, Faculté des Sciences Pharmaceutiques et Biologiques, Paris, F-75270 cedex France; ENSCP, Paris, F-75231 Cedex France. [thomas.maldiney@parisdescartes.fr](mailto:thomas.maldiney@parisdescartes.fr)

**ALBERTO MALERBA**

School of Biological Sciences, Royal Holloway, University of London, Egham Hill, Egham, Surrey, TW20 0EX, United Kingdom.

**CHRISTOPHER MANN**

Center of Animal Biotechnology and Gene Therapy and Department of Biochemistry and Molecular Biology, School of Veterinary Medicine, Universitat Autònoma de Barcelona, 08193-Bellaterra, Spain.

**CORINNE MARIE**

UPCGI, Inserm U1022 - CNRS UMR8151, Faculté des Sciences Pharmaceutiques et Biologiques, 4, avenue de l'Observatoire, 75270 Paris Cedex 06, France.

[corinne.marie@parisdescartes.fr](mailto:corinne.marie@parisdescartes.fr)

**PAULA MARQUES ALVES**

Instituto de Tecnologia Química e Biológica-Universidade Nova de Lisboa/Instituto de Biologia Experimental e Tecnológica (ITQB-UNL/IBET), P-2781-901 Oeiras, Portugal.

**OTTO-WILHELM MERTEN**

Généthon, 1, rue de l'Internationale, BP60, F-91000 Évry Cedex, France.



**WILHELM MEYRING**

Department of Molecular Biotechnology, Helmholtz Centre for Infection Research (HZI), Inhoffenstr. 7, Institute for Clinical Transfusion Medicine, Städtisches Klinikum Braunschweig gGmbH, D-38124 Braunschweig, Germany.

**NATHALIE MIGNET**

CNRS, UMR8151, Inserm, U1022, Université Paris Descartes, Sorbonne Paris-Cité, Faculté de Pharmacie, Chemical and Genetic Pharmacology and Imaging Laboratory, Paris, F-75270 France; École Nationale Supérieure de Chimie de Paris, Chimie ParisTech, Paris, F-75005 France.

**FEDERICO MINGOZZI**

Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA. [mingozzi@email.chop.edu](mailto:mingozzi@email.chop.edu)

**KYRIACOS MITROPHANOUS**

Oxford BioMedica plc, The Oxford Science Park, Medawar Centre, Oxford OX4 4GA, United Kingdom.

**UTE MODLICH**

Hannover Medical School (MHH) Institute of Experimental Haematology, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany.

**PARISA MONFARED**

<sup>1</sup>Laboratory for Gene Therapy and Molecular Imaging at the Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch-Laboratories of the Max Planck Society and the Faculty of Medicine of the University of Cologne, Cologne, Germany; <sup>2</sup>European Institute for Molecular Imaging (EIMI), University of Münster (WWU), Münster, Germany.

**EUGENIO MONTINI**

San Raffaele Telethon Institute for Gene Therapy, Milano, Italy.

**PHILIPPE MOULLIER**

Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, FL, USA; Laboratoire de Thérapie Génique, Inserm UMR649, CHU de Nantes, IRT UN, 30 boulevard Jean Monnet, F-44035 Nantes Cedex 1, France; Généthon, Évry, France. [moullier@ufl.edu](mailto:moullier@ufl.edu)

**LUIGI NALDINI**

San Raffaele Telethon Institute for Gene Therapy, Department of Regenerative Medicine, Stem Cells and Gene Therapy, San Raffaele Institute Milan, Via Olgettina-58, 20132 Milan, Italy.

**AMIT C. NATHWANI**

Department of Haematology, UCL Cancer Institute; Katharine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free NHS Trust, United Kingdom; National Health Services Blood and Transplant, United Kingdom. [amit.nathwani@ucl.ac.uk](mailto:amit.nathwani@ucl.ac.uk)

**ARTHUR W. NIENHUIS**

Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA.

**STÉPHANE PALFI**

Service de neurochirurgie Hôpital Henri Mondor, 51, avenue du Maréchal de Lattre de Tassigny, UPEC, Faculté de Médecine, 94010 Créteil Cedex, France.  
[stephane.palfi@hmn.aphp.fr](mailto:stephane.palfi@hmn.aphp.fr)

**AMOS PANET**

Departments of Biochemistry and Surgery, the Hebrew University-Hadassah Medical School, IMRIC, Jerusalem, Israel. [paneta@cc.huji.ac.il](mailto:paneta@cc.huji.ac.il)

**FRÉDÉRIC PÂQUES**

Cellectis S.A. 8, rue de la Croix Jarry, 75013 Paris, France.

**CRISTINA PEIXOTO**

IBET, Apartado 12, 2781-901 Oeiras, Portugal.

**SUSANNE POHL**

Helmholtz-Centre for Infection Research, Inhoffenstr. 7, D-38124 Braunschweig, Germany.

**LINDA POPPLEWELL**

School of Biological Sciences, Royal Holloway, University of London, Egham Hill, Egham, Surrey, TW20 0EX, United Kingdom.

**DEEPAK RAJ**

Department of Haematology, UCL Cancer Institute; National Health Services Blood and Transplant, United Kingdom.

**R. SCOTT RALPH**

Oxford BioMedica plc, The Oxford Science Park, Medawar Centre, Oxford OX4 4GA, United Kingdom.

**ULRIKE REISS**

Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA.

**CYRILLE RICHARD**

Unité de Pharmacologie Chimique et Génétique et d'Imagerie; CNRS, UMR 8151, Inserm, U 1022, Université Paris Descartes, Sorbonne Paris-Cité, Faculté des Sciences Pharmaceutiques et Biologiques, Paris, F-75270 cedex France; ENSCP, Paris, F-75231 Cedex, France. [cyrille.richard@parisdescartes.fr](mailto:cyrille.richard@parisdescartes.fr)

**ANJA RISCHMÜLLER**

PlasmidFactory GmbH and Co. KG, Meisenstrasse 96, D-33607 Bielefeld, Germany.

**ANA F. RODRIGUES**

Instituto de Tecnologia Química e Biológica-Universidade Nova de Lisboa/Instituto de Biologia Experimental e Tecnológica (ITQB-UNL/IBET), P-2781-901 Oeiras, Portugal.

**MICHELLE ROSENZWAJG**

Université Pierre et Marie Curie, UPMC Université Paris 06, CNRS UMR7211, Inserm U959, Hôpital Pitié-Salpêtrière, 83, boulevard de l'Hôpital, 75013 Paris, France; Clinical Investigation Center in Biotherapy, AP-HP, Hôpital Pitié-Salpêtrière, F-75651, Paris 13, France.

**JORGE M. SANTOS**

ECBio, S.A., R. Henrique Paiva Couceiro, 27, 2700-451 Amadora, Portugal.

**SONJA SCHÄFERS**

European Institute for Molecular Imaging (EIMI), University of Münster (WWU), Münster, Germany.

**AXEL SCHAMBACH**

Hannover Medical School (MHH) Institute of Experimental Haematology, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany.

**THOMAS SCHASER**

Miltenyi Biotec GmbH, Bergisch Gladbach, Germany.

**DANIEL SCHERMAN**

UPCGI, CNRS, UMR8151, Inserm, U1022, Université Paris Descartes, Sorbonne Paris-Cité, Faculté de Pharmacie, Chemical and Genetic Pharmacology and Imaging Laboratory, F-75270, Paris Cedex 06, France; École Nationale Supérieure de Chimie de Paris, Chimie ParisTech, Paris, F-75005 France. [daniel.scherman@parisdescartes.fr](mailto:daniel.scherman@parisdescartes.fr)

**MARTIN SCHLEEF**

PlasmidFactory GmbH and Co. KG, Meisenstrasse 96, D-33607 Bielefeld, Germany. [martin.schleef@plasmidfactory.com](mailto:martin.schleef@plasmidfactory.com)

**MARCO SCHMEER**

PlasmidFactory GmbH and Co. KG, Meisenstrasse 96, D-33607 Bielefeld, Germany.

**MANFRED SCHMIDT**

Department of Translational Oncology, National Center for Tumor Diseases NCT and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

**MATTHIAS SCHWEIZER**

Paul-Ehrlich-Institut, Paul-Ehrlich-Straße 51-59, 63225 Langen, Germany. [matthias.schweizer@pei.de](mailto:matthias.schweizer@pei.de)

**ÅKE SEIGER**

Department of Neurobiology, Caring Sciences and Society, Division of Clinical Geriatrics, Karolinska Institutet, Sweden; Department of Geriatrics, Karolinska University Hospital, Stockholm, Sweden.

**ANA CARINA SILVA**

IBET, Apartado 12, 2781-901 Oeiras, Portugal; ITQB-UNL, Apartado 12, 2781-901 Oeiras, Portugal.

**DANIEL SIMÃO**

IBET, Apartado 12, 2781-901 Oeiras, Portugal.

**ADRIEN SIX**

UPMC Université Paris 06, CNRS, UMR 7211, Inserm, U959, Bâtiment CERVI, Hôpital Pitié-Salpêtrière, 83, boulevard de l'Hôpital, F-75013 Paris, France.

**JULIANNE SMITH**

Collectis Therapeutics, 8, rue de la Croix Jarry, 75013 Paris, France. [smith@collectis.com](mailto:smith@collectis.com)

**ALEXANDER J. SMITH**

UCL Institute of Ophthalmology, Department of Genetics, 11-43 Bath Street, London EC1V 9EL, United Kingdom.

**RICHARD O. SNYDER**

Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, FL, USA; Laboratoire de Thérapie Génique, Inserm UMR649, IRT UN, Nantes, France; Department of Pediatrics, College of Medicine, University of Florida, FL, USA.

**MARCOS F.Q. SOUSA**

IBET, Apartado 12, 2781-901 Oeiras, Portugal.

**JULIA D. SUERTH**

Hannover Medical School (MHH) Institute of Experimental Haematology, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany.

**ERIK SUNDSTRÖM**

Department of Neurobiology, Caring Sciences and Society, Division of Clinical Geriatrics, Karolinska Institutet, Sweden; Stockholms Sjukhem, Stockholm, Sweden.

**SHAY TAYEB**

Departments of Biochemistry and Surgery, the Hebrew University-Hadassah Medical School, IMRIC, Jerusalem, Israel.

**MICHAEL THOMAS**

Fraunhofer-Institut für Schicht- und Oberflächentechnik (IST), Braunschweig, Germany.

**VÉRONIQUE THOMAS-VASLIN**

UPMC Université Paris 06, CNRS, UMR 7211, Inserm, U959, Bâtiment CERVI, Hôpital Pitié-Salpêtrière, 83, boulevard de l'Hôpital, F-75013 Paris, France.

**EDWARD G.D. TUDDENHAM**

Department of Haematology, UCL Cancer Institute; Katharine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free NHS Trust, United Kingdom.

**THIERRY VANDENDRIESSCHE**

Department of Gene Therapy and Regenerative Medicine, Free University of Brussels (VUB), Faculty of Medicine and Pharmacy, University Medical Center - Jette, Laarbeeklaan 103, B-1090 Brussels, Belgium; Department of Molecular Cardiovascular Medicine, University of Leuven, University Hospital Campus Gasthuisberg, Belgium. [thierry.vandendriessche@vub.ac.be](mailto:thierry.vandendriessche@vub.ac.be)

**ELS VERHOEYEN**

Inserm, EVIR, U758, Human Virology Department, École Normale Supérieure de Lyon, Université Lyon 1, F-69007, Lyon, France. [els.verhoeyen@ens-lyon.fr](mailto:els.verhoeyen@ens-lyon.fr)

**INDER M. VERMA**

Irwin and Joan Jacobs Chair in Exemplary Life Science, American Cancer Society Professor of Molecular Biology, Laboratory of Genetics, The Salk Institute, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA. [verma@salk.edu](mailto:verma@salk.edu)

**THOMAS VIEL**

<sup>1</sup>Laboratory for Gene Therapy and Molecular Imaging at the Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch-Laboratories of the Max Planck Society and the Faculty of Medicine of the University of Cologne, Cologne, Germany; <sup>2</sup>European Institute for Molecular Imaging (EIMI), University of Münster (WWU), Münster, Germany.

**YANNIC WAERZEGGERS**

<sup>1</sup>Laboratory for Gene Therapy and Molecular Imaging at the Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch-Laboratories of the Max Planck Society and the Faculty of Medicine of the University of Cologne, Cologne, Germany; <sup>2</sup>European Institute for Molecular Imaging (EIMI), University of Münster (WWU), Münster, Germany.

**LARS WAHLBERG**

Department of Neurobiology, Caring Sciences and Society, Division of Clinical Geriatrics, Karolinska Institutet, Sweden; NsGene A/S, Ballerup, Denmark.

**ALEXANDRA WINKELER**

<sup>1</sup>Laboratory for Gene Therapy and Molecular Imaging at the Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch-Laboratories of the Max Planck Society and the Faculty of Medicine of the University of Cologne, Cologne, Germany; <sup>2</sup>Laboratory for Experimental Molecular Imaging, Inserm U1023, University Paris Sud, Paris, France.

**DAGMAR WIRTH**

Model Systems for Infection (MSYS), Helmholtz-Zentrum für Infektionsforschung, Inhoffenstr. 7, D-38124 Braunschweig, Germany. [dkl@helmholtz-hzi.de](mailto:dkl@helmholtz-hzi.de)

**SEPPO YLÄ-HERTTUALA**

A.I. Virtanen Institute, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland. [seppo.ylarherttuala@uef.fi](mailto:seppo.ylarherttuala@uef.fi)

**SERENA ZACCHIGNA**

Molecular Medicine Laboratory, International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 99, 34149 Trieste, Italy.

**GIDI ZAMIR**

Departments of Biochemistry and Surgery, the Hebrew University-Hadassah Medical School, IMRIC, Jerusalem, Israel.



# Contents

<b>CLINIGENE PARTNERS AND BOARDS</b> .....	IX
<b>ACKNOWLEDGMENTS</b> .....	XV
<b>LIST OF AUTHORS</b> .....	XVII

## INTRODUCTION

<b>In-1 Foreword</b>	
Lucio Luzzatto, Inder M. Verma .....	3
<b>In-2 Main achievements and prospects downstream of the CliniGene-NoE</b>	
Odile Cohen-Haguenaer .....	8

## PART I: TECHNOLOGIES AND PRE-CLINICAL STUDIES

### TECHNOLOGIES - Highlights on AAV mediated gene transfer

<b>A1-1 Highlights on AAV mediated gene transfer: introduction</b>	
Eduard Ayuso, Fatima Bosch .....	31
<b>A1-2 Preclinical studies of AAV gene therapy for inherited retinal dystrophies</b>	
Alexander J. Smith, Anastasios Georgiadis, Robin R. Ali .....	35
<b>A1-3 AAV-mediated gene therapy for MPS VI</b>	
Gabiella Cotugno, Patrizia Annunziata, Mark Haskins, Alberto Auricchio ..	41
<b>A1-4 Microdystrophin and myostatin gene therapy for Duchenne muscular dystrophy using adeno-associated virus vectors</b>	
Helen Foster, Taeyoung Koo, Alberto Malerba, Susan Jarmin, Takis Athanasopoulos, Keith Foster, George Dickson .....	46
<b>A1-5 AAV gene therapy for cardiovascular disorders</b>	
Serena Zacchigna, Mauro Giacca .....	55
<b>A1-6 AAV gene therapy for diabetes mellitus</b>	
Eduard Ayuso, Veronica Jimenez, David Callejas, Christopher Mann, Fatima Bosch .....	62
<b>A1-7 Approaches to large scale production of AAV-vectors</b>	
Otto-Wilhelm Merten, Philippe Moullier .....	71

<b>A1-8 Reference materials for the characterization of adeno-associated viral vectors</b>	
Eduard Ayuso, Véronique Blouin, Christophe Darmon, Fatima Bosch, Martin Lock, Richard O. Snyder, Philippe Moullier . . . . .	83

**TECHNOLOGIES - Retrovirus mediated gene transfer state-of-the-art**

<b>A2-1 Highlights on retrovirus mediated gene transfer</b>	
Pedro E. Cruz, Manuel J.T. Carrondo . . . . .	93
<b>A2-2 Retroviral vector development: reducing genotoxicity of integrated DNA and creating virus-like particles for transient cell modification</b>	
Melanie Galla, Tobias Maetzig, Julia D. Suerth, Ute Modlich, Axel Schambach, Christopher Baum . . . . .	100
<b>A2-3 Replication competent <math>\gamma</math>-retroviral vectors for tumor therapy</b>	
Thomas Schaser, Lydia Dürner, Klaus Cichutek, Christian J. Buchholz . . . .	112
<b>A2-4 Modular retroviral producer cell lines</b>	
Ana Sofia Coroadinha, Dagmar Wirth, Ana F. Rodrigues, Leonor Gama-Norton, Caroline Duros, Alexandre Artus, Odile Cohen-Haguenaer, Paula Marques Alves, Pedro E. Cruz, Manuel J.T. Carrondo, Hansjörg Hauser . . . . .	118

**TECHNOLOGIES - Highlights on lentivirus mediated gene transfer**

<b>A3-1 Introduction</b>	
Matthias Schweizer, Klaus Cichutek . . . . .	127
<b>A3-2 MicroRNAs detargeting technology in the context of CNS applications</b>	
Angélique Colin, Mathilde Faideau, Noëlle Dufour, Gwennaëlle Auregan, Raymonde Hassig, Carole Escartin, Philippe Hantraye, Gilles Bonvento, Nicole Déglon . . . . .	129
<b>A3-3 Development of SIVsmmPBj vectors for gene transfer into myeloid cells</b>	
Matthias Schweizer, Klaus Cichutek . . . . .	134
<b>A3-4 Insulated retrovirus vectors using novel synthetic genetic insulator elements to circumvent enhancer-mediated genotoxicity</b>	
Caroline Duros, Alexandre Artus, Odile Cohen-Haguenaer . . . . .	138
<b>A3-5 Facing the challenges of downstream processing of lentiviral vectors</b>	
Vanessa Bandeira, Cristina Peixoto, Ana Sofia Coroadinha, Pedro E. Cruz, Manuel J.T. Carrondo, Otto-Wilhelm Merten, Paula Marques Alves . . . . .	150
<b>A3-6 Restrictions and requirements for stable lentiviral vector production in HEK293 cells</b>	
Leonor Gama-Norton, Hansjörg Hauser, Dagmar Wirth . . . . .	156



<b>A3-7 Novel lentiviral vector pseudotypes for stable gene transfer into resting hematopoietic cells</b>	
Els Verhoeyen, François-Loïc Cosset . . . . .	160

**TECHNOLOGIES - Highlights on gene-modified cell therapy**

<b>A4-1 Cell therapy: introduction</b>	
Gösta Gahrton . . . . .	185
<b>A4-2 <i>Ex-vivo</i> expansion of human mesenchymal stem cells</b>	
Pedro E. Cruz, Helder J.S. Cruz, Rita N. Bárcia, Jorge M. Santos, Susanne Pohl, Mari Gilljam, Kurt E.J. Dittmar, Werner Lindenmaier, Evren Alici . . . . .	187
<b>A4-3 Closed bag cultivation systems for the production of gene modified dendritic cells and MSC for clinical use</b>	
Werner Lindenmaier, Lars Macke, Wilhelm Meyring, Henk S.P. Garritsen, Kurt E.J. Dittmar, Kristina Lachmann, Michael Thomas . . . . .	194
<b>A4-4 Genetically modified NK cells for cancer treatment: facts and visions</b>	
Evren Alici, Gösta Gahrton . . . . .	201
<b>A4-5 Regulatory T lymphocyte depletion for cancer immunotherapies</b>	
Michelle Rosenzweig, François Lemoine, David Klatzmann . . . . .	208
<b>A4-6 Gene therapy of Fanconi's anaemia aplastic syndrome</b>	
Émilie Bayart, Caroline Duros, Alexandre Artus, Stéphanie Lemaire, Odile Cohen-Haguenaer . . . . .	216

**TECHNOLOGIES - Adenovirus mediated gene transfer: current developments**

<b>A5-1 Overview on adenovirus vectors</b>	
Stefan Kochanek . . . . .	229
<b>A5-2 Tumour barriers influencing adenovirus vector delivery and therapeutic efficacy</b>	
Tanja Lucas, Stefan Kochanek . . . . .	232
<b>A5-3 Tumor imaging with adenoviral vectors</b>	
Martina Anton, Bernd Gänsbacher . . . . .	238
<b>A5-4 Treatment of brain tumors with adenoviruses: preclinical development</b>	
Seppo Ylä-Herttua . . . . .	242
<b>A5-5 Production and purification of Ad vectors: current status and future needs for adenovirus vector production</b>	
Ana Carina Silva, Daniel Simão, Marcos F.Q. Sousa, Cristina Peixoto, Pedro E. Cruz, Manuel J.T. Carrondo, Paula Marques Alves . . . . .	245

## **TECHNOLOGIES - Non-viral based gene transfer: a new era**

<b>A6-1 Non viral plasmid delivery and imaging of transgene expression</b>	
Pascal Bigey, Michel-Francis Bureau, Gonzalo Cordova, Virginie Escriou, Antoine Kichler, Nathalie Mignet, Daniel Scherman . . . . .	253
<b>A6-2 Overview of novel plasmid vectors and preclinical applications</b>	
Corinne Marie, Daniel Scherman . . . . .	266
<b>A6-3 Filling a gap: S/MAR-based replicating minicircles</b>	
Niels Heinz, Sandra Broll, Martin Schleef, Christopher Baum, Juergen Bode . . . . .	271
<b>A6-4 Manufacturing and QC of plasmid based vectors</b>	
Marco Schmeer, Martin Schleef . . . . .	277
<b>A6-5 <i>Sleeping Beauty</i> transposon based gene therapy</b>	
Zsuzsanna Izsvák, Zoltán Ivics . . . . .	284
<b>A6-6 Development of <i>minicircle</i> vectors</b>	
Marco Schmeer, Anja Rischmüller, Martin Schleef . . . . .	290
<b>A6-7 Exon skipping therapy for DMD using antisense oligomer technology</b>	
Linda Popplewell, Jagjeet Kang, Alberto Malerba, Keith Foster, George Dickson . . . . .	295

## **TECHNOLOGIES - Highlights on iPS induction, genetic stability and emerging technologies**

<b>A7-1 Induction of pluripotency from adult somatic cells: a review</b>	
Émilie Bayart, Odile Cohen-Haguenaer . . . . .	307
<b>A7-2 Genetic modification of adult stem cells and induced pluripotent stem cells with emerging transposon technologies</b>	
Thierry VandenDriessche, Marinee K.L. Chuah . . . . .	335
<b>A7-3 Targeted genome engineering approaches based on rare-cutting endonucleases: a tentative summary</b>	
Frédéric Pâques, Julianne Smith . . . . .	341
<b>A7-4 Targeted genome modifications with designer nucleases</b>	
Christien Bednarski, Eva-Maria Händel, Toni Cathomen . . . . .	354

## **PRE-CLINICAL STUDIES, BIOSAFETY AND ANIMAL MODELS - Preclinical assessment tools**

<b>B1-1 Preclinical assessment tools: imaging gene transfer to the brain</b>	
Yannic Waerzeggers, Thomas Viel, Sonja Schäfers, Parisa Monfared, Alexandra Winkeler, Andreas H. Jacobs . . . . .	371

<b>B1-2</b>	<b>Persistent luminescence nanoparticles for <i>in vivo</i> imaging: characteristics and targeting</b>	
	Thomas Maldiney, Daniel Scherman, Cyrille Richard . . . . .	386
<b>B1-3</b>	<b><i>Ex-vivo</i> evaluation of gene-transfer vectors: efficacy, tropism and safety</b>	
	Dror Kolodkin-Gal, Shay Tayeb, Abed Khalaileh, Gidi Zamir, Nikolai Kunicher, Amos Panet . . . . .	394
<b>PRE-CLINICAL STUDIES, BIOSAFETY AND ANIMAL MODELS - General biosafety: immune responses, immunotoxicity and genotoxicity</b>		
<b>B2-1</b>	<b>Assessing and taming unwanted immune responses induced by AAV gene transfer: current status, ongoing questions and future prospects</b>	
	Federico Mingozzi, Anne Galy, David Klatzmann . . . . .	405
<b>B2-2</b>	<b>Predicting immune responses to viral vectors and transgenes in gene therapy and vaccination: the coming of systems biology</b>	
	Bertrand Bellier, Adrien Six, Véronique Thomas-Vaslin, David Klatzmann . . . . .	420
<b>B2-3</b>	<b>Biosafety analysis in preclinical and clinical studies</b>	
	Manfred Schmidt, Stephanie Laufs, Alessandro Aiuti, Patrick Aubourg, Christopher Baum, Luca Biasco, Nathalie Cartier, Hansjörg Hauser, Eugenio Montini, Philippe Moullier, Richard O. Snyder, Dagmar Wirth, Christof von Kalle . . . . .	432

## **PART II: CLINICAL TRIALS AND REGULATORY ISSUES**

### **CLINICAL TRIALS**

<b>C1-1</b>	<b>A clinical trial of AAV-mediated gene therapy for Leber congenital amaurosis 2</b>	
	Alexander J. Smith, Robin R. Ali . . . . .	447
<b>C1-2</b>	<b>Gene therapy for X-linked adrenoleukodystrophy based on lentiviral correction of hematopoietic stem cells</b>	
	Nathalie Cartier, Salima Hacein-Bey-Abina, Cynthia C. Bartholomae, Manfred Schmidt, Christof von Kalle, Pierre Bougnères, Alain Fischer, Marina Cavazzana-Calvo, Patrick Aubourg . . . . .	452
<b>C1-3</b>	<b>Immune reconstitution after gene therapy for adenosine deaminase severe combined immunodeficiency (ADA-SCID)</b>	
	Immacolata Brigida, Alessandro Aiuti . . . . .	459
<b>C1-4</b>	<b>Gene therapy in Alzheimer disease patients</b>	
	Maria Eriksson-Jönköping, Bengt Linderöth, Per Almqvist, Göran Lind, Helga Eyjolfsson, Erik Sundström, Åke Seiger, Lars Wahlberg . . . . .	465

<b>C1-5 Cardiovascular gene therapy trials</b>	
Seppo Ylä-Herttuala . . . . .	475
<b>C1-6 AAV-mediated gene therapy for haemophilia B</b>	
Deepak Raj, Edward G.D. Tuddenham, Arthur W. Nienhuis, Ulrike Reiss, Andrew M. Davidoff, Amit C. Nathwani . . . . .	479
<b>C1-7 ProSavin®: a lentiviral vector approach for the treatment of Parkinson’s disease</b>	
Stéphane Palfi , R. Scott Ralph, Kyriacos Mitrophanous . . . . .	486

**ETHICAL AND REGULATORY ISSUES**

<b>C2-1 Ethics in translation from research to therapy</b>	
Nancy M.P. King, Odile Cohen-Haguenaer, Alastair Kent . . . . .	495
<b>C2-2 Centralised regulation of gene therapy in Europe</b>	
Odile Cohen-Haguenaer . . . . .	504
<b>C2-3 The necessity for data sharing towards advancement of clinical translation: building up sample IMPD and substantiating master files</b>	
Odile Cohen-Haguenaer . . . . .	517

**INTEGRATION AND DISSEMINATION**

<b>C3-1 European Union support to gene transfer and gene therapy</b>	
Ruxandra Draghia-Akli . . . . .	531
<b>C3-2 Database of clinical trials</b>	
Bernd Gänsbacher . . . . .	533
<b>C3-3 CliniGene and ESGCT shared vision for gene therapy in Europe: past, present and future prospects</b>	
Thierry VandenDriessche, Bernd Gänsbacher, George Dickson, David Klatzmann, Seppo Ylä-Herttuala, Luigi Naldini, Alastair Kent, Odile Cohen-Haguenaer . . . . .	536

<b>AUTHOR INDEX . . . . .</b>	<b>541</b>
-------------------------------	------------